Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICES13
- Development stage
- Unknown
- Lead developer
- Innovacell Biotechnology
- Modality
- Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intramuscular
01
Overview
ICES13 is an autologous skeletal muscle-derived cell therapy developed for the treatment of stress urinary incontinence. The therapy involves isolating healthy muscle stem cells from a small biopsy of the patient’s own skeletal muscle, expanding these cells in vitro to obtain sufficient numbers, and then injecting them into the weakened or injured sphincter muscle using a minimally invasive procedure. The goal is to regenerate and strengthen the sphincter by promoting new muscle formation and restoring its function, thereby addressing the underlying cause of stress urinary incontinence rather than just alleviating symptoms. ICES13 has completed phase II clinical trials and is preparing for multi-regional phase III trials across Japan, Europe, and the USA.
- Other names
- skeletal muscle-derived cell therapyautologous skeletal muscle-derived cells
Beyond the preview
Go deeper on ICES13.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICES13.